The new POLE-POLD1 assay for the Idylla™ system enables molecular diagnostics of endometrial carcinoma directly from an FFPE section in just 95 minutes. This ultra-fast analysis supports prognostic assessment and treatment stratification already at the early stages of care. Endometrial cancer is the fourth most common cancer among women in Finland, and molecular profiling is an essential part of its diagnostics.
ESMO recommends classifying all endometrial carcinomas into four molecular profiles:
• POLE-abnormal
• MMR-deficient
• P53-abnormal
• NSMP (non-specific molecular profile)
Mutations in the POLE and POLD1 genes disrupt the genome’s proofreading function, leading to a hypermutated tumor genotype and an increased number of neoantigens. Such tumors are often associated with a better prognosis and patients may benefit from immunotherapy.
Biocartis’ Idylla™ POLE-POLD1 test requires only a single FFPE section and covers 99% of pathogenic POLE and POLD1 mutations. The POLE-POLD1 test complements the Idylla™ system’s broad oncology diagnostics portfolio and enables molecular profiling for endometrial carcenoma faster than ever before.
More information:
Miika Palviainen
miika.palviainen@algol.fi
tel: +358 50 587 5030
Miro Nevalainen
miro.nevalainen@algol.fi
tel: +358 40 182 7613